RT Journal Article
SR Electronic
T1 Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.10.20246827
DO 10.1101/2020.12.10.20246827
A1 Thomas N. Vilches
A1 Kevin Zhang
A1 Robert Van Exan
A1 Joanne M. Langley
A1 Seyed M. Moghadas
YR 2021
UL http://medrxiv.org/content/early/2021/03/18/2020.12.10.20246827.abstract
AB Background A number of highly effective COVID-19 vaccines have been developed and approved for mass vaccination. We evaluated the impact of vaccination on COVID-19 outbreak and disease outcomes in Ontario, Canada.Methods We used an agent-based transmission model and parameterized it with COVID-19 characteristics, demographics of Ontario, and age-specific clinical outcomes. We implemented a two-dose vaccination program according to tested schedules in clinical trials for Pfizer-BioNTech and Moderna vaccines, prioritizing healthcare workers, individuals with comorbidities, and those aged 65 and older. Daily vaccination rate was parameterized based on vaccine administration data. Using estimates of vaccine efficacy, we projected the impact of vaccination on the overall attack rate, hospitalizations, and deaths. We further investigated the effect of increased daily contacts at different stages during vaccination campaigns on outbreak control.Results Maintaining non-pharmaceutical interventions (NPIs) with an average of 74% reduction in daily contacts, vaccination with Pfizer-BioNTech and Moderna vaccines was projected to reduce hospitalizations by 27.3% (95% CrI: 22.3% - 32.4%) and 27.0% (95% CrI: 21.9% - 32.6%), respectively, over a one-year time horizon. The largest benefits of vaccination were observed in preventing deaths with reductions of 31.5% (95% CrI: 22.5% - 39.7%) and 31.9% (95% CrI: 22.0% - 41.4%) for Pfizer-BioNTech and Moderna vaccines, respectively, compared to no vaccination. We found that an increase of only 10% in daily contacts at the end of lockdown, when vaccination coverage with only one dose was 6%, would trigger a surge in the outbreak. Early relaxation of population-wide measures could lead to a substantial increase in the number of infections, potentially reaching levels observed during the peak of the second wave in Ontario.Conclusions Vaccination can substantially mitigate ongoing COVID-19 outbreaks. Sustaining population-wide NPIs, to allow for a sufficient increase in population-level immunity through vaccination, is essential to prevent future outbreaks.Competing Interest StatementJML's institution has received funding for research studies from Sanofi Pasteur, GlaxoSmithKline, Merck, Janssen, Medicago, VBI, VIDO, Entos and Pfizer. JML holds the CIHR-GSK Chair in Paediatric Vaccinology. Other authors declare no competing interests.Funding StatementSMM gratefully acknowledges the Canadian Institutes of Health Research OV4-170643, COVID-19 Rapid Research; and Natural Sciences and Engineering Research Council of Canada. TNV acknowledges the support of the São Paulo Research Foundation, grant #2018/24811-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not required as all data is publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe model was coded in Julia language and is available at: https://github.com/thomasvilches/vac_covid_ontario. https://github.com/thomasvilches/vac_covid_ontario